Form 4: Blueprint Medicines Director Lonnel Coats Reports Stock and Option Grants

Director Lonnel Coats received restricted stock units and stock options from Blueprint Medicines Corp on June 12, 2024.

Summary

• On June 12, 2024, Lonnel Coats, a director of Blueprint Medicines Corp, reported the acquisition of 2,242 shares of common stock and stock options for 4,570 shares.
• The common stock was received as a grant of restricted stock units.
• These restricted stock units vest on the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders.
• Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• The stock options, with an exercise price of $106.14, also vest on the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders and expire on June 12, 2034.
• Following these transactions, Coats directly owns 13,254 shares of common stock and options for 4,570 shares.

Sentiment

Score: 6

Explanation: The document reflects a routine grant of stock and options, which is generally neutral. It indicates ongoing compensation practices and alignment of interests.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company's success.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon continued service until the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders.

Industry Context

Grants of stock options and restricted stock units are common compensation practices in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules are also standard, usually tied to continued employment to align executive interests with long-term shareholder value.
• Companies like Amgen, Gilead, and Vertex also utilize similar equity-based compensation strategies.

Stakeholder Impact

• The grant of equity to a director aligns their interests with those of shareholders, potentially driving long-term value creation.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates